Institute of Stem Cells of the University of Ankar, with the support of the Tubitak Scientific and Technological Research Council (Tubitak), developed a domestic drug against mutating a new type of coronavirus, report “TRT in Russian”.
Scientists reported that the laboratory tests of the drug “Ribavirin”, which will be used in the treatment of patients with COVID-19, successfully completed after the drug has shown its effectiveness.
The clinical phase of the tests will begin after 1-2 weeks with the participation of 50 volunteer patients, mainly in the hospital IBN and Sina at the University of Ankara, as well as at the University of Koch, a training hospital in the University of Ankara.